Home › Breast Cancer › NCT07318051
Sample Collection for Ongoing Research and Product Evaluation Study
Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. 18 years of age or older. 2. Any patient that has an untreated primary solid malignancy within the following cohorts: 1. Breast cancer 2. Lung cancer 3. Muscle invasive bladder cancer 4. Rectal cancer 5. Pancreatic cancer 6. Ovarian cancer 7. Gastroesophageal cancer 8. Prostate cancer 9. Melanoma 10. Hepatic/liver cancer 11. Uterine/endometrial cancer 12. Head and neck Cancer 3. The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging. 4. Eastern Cooperative Oncology Group performance status ≤ 2. 5. Able to tolerate venipuncture for research blood draw(s). 6. Consent to provide residual tumor tissue for research. 7. Willing and able to comply with the study requirements. 8. Signed informed consent(s) must be obtained prior to participation in the study. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers. 3. Has initiated postoperative systemic treatment. 4. At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection. 5. History of bone marrow or organ transplant. 6. Serious medical conditions that may adversely affect ability to participate in the study.
About the study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
Sponsor: Natera, Inc. · Participants: 9,600 · Started: Jul 21, 2025
Contact the study team
- SCORE Study team · Phone: 650-489-9050
Official record on ClinicalTrials.gov — NCT07318051
Locations in the U.S.
| Texas | Natera, Inc., Austin |
Conditions
- Breast Cancer
- Lung Cancer
- Rectal Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Prostate Cancer
- Melanoma
- Head and Neck Cancer
- Uterine Cancer
- Liver Cancer
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.